Terms: = Lung cancer AND PSA AND Staging
22 results:
1. Ductal prostate cancer staging: Role of PSMA PET/CT.
Pepe P; Pepe L; Curduman M; Pennisi M; Fraggetta F
Arch Ital Urol Androl; 2024 Feb; 96(1):12132. PubMed ID: 38363231
[TBL] [Abstract] [Full Text] [Related]
2. A Web-Based Prediction Model for cancer-Specific Survival of Elderly Patients Undergoing Surgery With Prostate cancer: A Population-Based Study.
Zhang Z; Zhanghuang C; Wang J; Mi T; Liu J; Tian X; Jin L; He D
Front Public Health; 2022; 10():935521. PubMed ID: 35903379
[TBL] [Abstract] [Full Text] [Related]
3. Identification and Validation of the Prognostic Impact of Metastatic Prostate cancer Phenotypes.
Labe SA; Wang X; Lehrer EJ; Kishan AU; Spratt DE; Lin C; Morgans AK; Ponsky L; Garcia JA; Garrett S; Wang M; Zaorsky NG
Clin Genitourin Cancer; 2022 Aug; 20(4):371-380. PubMed ID: 35383004
[TBL] [Abstract] [Full Text] [Related]
4. 68Ga-PSMA PET/CT With Incidental Finding of COVID-19 in an Asymptomatic Patient.
Morón S; González E; Rojas J
Clin Nucl Med; 2020 Dec; 45(12):1032-1033. PubMed ID: 33065616
[TBL] [Abstract] [Full Text] [Related]
5. A Limited-Versus-Extensive staging Strategy for Small Cell Prostate cancer.
Syed S; Basourakos SP; Ali FS; Garcia JL; Zurita-Saavedra A; Gong Z
Am J Clin Oncol; 2020 Feb; 43(2):87-93. PubMed ID: 31764016
[TBL] [Abstract] [Full Text] [Related]
6. Application of Cu-64 NODAGA-PSMA PET in Prostate cancer.
Sevcenco S; Klingler HC; Eredics K; Friedl A; Schneeweiss J; Knoll P; Kunit T; Lusuardi L; Mirzaei S
Adv Ther; 2018 Jun; 35(6):779-784. PubMed ID: 29777523
[TBL] [Abstract] [Full Text] [Related]
7. Pattern and Distribution of Distant Metastases in Anaplastic Prostate Carcinoma: A Single-Institute Experience With 101 Patients.
Ganeshan D; Aparicio AM; Morani A; Kundra V
AJR Am J Roentgenol; 2017 Aug; 209(2):327-332. PubMed ID: 28590819
[TBL] [Abstract] [Full Text] [Related]
8. Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist
Wieser G; Popp I; Christian Rischke H; Drendel V; Grosu AL; Bartholomä M; Weber WA; Mansi R; Wetterauer U; Schultze-Seemann W; Meyer PT; Jilg CA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1463-1472. PubMed ID: 28417160
[TBL] [Abstract] [Full Text] [Related]
9. EphA6 promotes angiogenesis and prostate cancer metastasis and is associated with human prostate cancer progression.
Li S; Ma Y; Xie C; Wu Z; Kang Z; Fang Z; Su B; Guan M
Oncotarget; 2015 Sep; 6(26):22587-97. PubMed ID: 26041887
[TBL] [Abstract] [Full Text] [Related]
10. Perivascular epithelioid cell tumor (PEC-ome) of the prostate: ultrasound feature in case report.
Sbrollini G; Conti A; Galosi AB; Lacetera V; Montironi R; Montesi L; Muzzonigro G
Arch Ital Urol Androl; 2014 Dec; 86(4):393-4. PubMed ID: 25641481
[TBL] [Abstract] [Full Text] [Related]
11. Heterogeneity of d-glucuronyl C5-epimerase expression and epigenetic regulation in prostate cancer.
Prudnikova TY; Soulitzis N; Kutsenko OS; Mostovich LA; Haraldson K; Ernberg I; Kashuba VI; Spandidos DA; Zabarovsky ER; Grigorieva EV
Cancer Med; 2013 Oct; 2(5):654-61. PubMed ID: 24403231
[TBL] [Abstract] [Full Text] [Related]
12. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
[TBL] [Abstract] [Full Text] [Related]
13. Analysis of IMP3 expression in prostate adenocarcinomas.
Tosun Yildirim H; Sentürk N
Turk Patoloji Derg; 2012; 28(2):128-33. PubMed ID: 22627630
[TBL] [Abstract] [Full Text] [Related]
14. Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy.
Fuccio C; Castellucci P; Schiavina R; Guidalotti PL; Gavaruzzi G; Montini GC; Nanni C; Marzola MC; Rubello D; Fanti S
Eur J Radiol; 2012 Aug; 81(8):e893-6. PubMed ID: 22621862
[TBL] [Abstract] [Full Text] [Related]
15. Chromogranin A--serum marker for prostate cancer.
Khan MO; Ather MH
J Pak Med Assoc; 2011 Jan; 61(1):108-11. PubMed ID: 22368921
[TBL] [Abstract] [Full Text] [Related]
16. [Tracers in oncology - preclinical and clinical evaluation].
Krause BJ; Schwarzenböck S; Schwaiger M
Nuklearmedizin; 2010; 49 Suppl 1():S41-5. PubMed ID: 21152689
[TBL] [Abstract] [Full Text] [Related]
17. [Contribution of psa and its density in the diagnosis and tracking of the prostate cancer].
Yousra S; Rafik E; Manel M; Kacem M
Ann Biol Clin (Paris); 2010; 68(5):585-93. PubMed ID: 20870581
[TBL] [Abstract] [Full Text] [Related]
18. [Radical transurethral resection of the prostate. An alternative therapy for the treatment of prostate cancer].
Reuter MA; Dietz K
Urologe A; 2009 Jul; 48(7):740-7. PubMed ID: 19484215
[TBL] [Abstract] [Full Text] [Related]
19. Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer.
Eschmann SM; Pfannenberg AC; Rieger A; Aschoff P; Müller M; Paulsen F; Anastasiadis A; Claussen CD; Bares R; Schlemmer HP
Nuklearmedizin; 2007; 46(5):161-8; quiz N47-8. PubMed ID: 17938748
[TBL] [Abstract] [Full Text] [Related]
20. [Treatment strategy for locally advanced prostate cancer].
Kurokawa K; Suzuki K; Yamanaka H
Gan To Kagaku Ryoho; 2003 Jan; 30(1):38-42. PubMed ID: 12557703
[TBL] [Abstract] [Full Text] [Related]
[Next]
